Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06743295 · ClinicalTrials.gov registry record · NA

AI Noise Reduction in Phonak Hearing Aids

A NA study of Hearing Loss, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
500
Enrollment target
1
Study location

NCT06743295: Recruiting NA study of Hearing Loss, sponsored by Mayo Clinic.

NCT06743295 is a NA study of Hearing Loss that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 500 participants, below the 6,112-participant average among 58 other Hearing Loss trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06743295, a NA study of Hearing Loss, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
500 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if artificial intelligence- based noise reduction can offer objective improvement in hearing and speech perception for hearing impaired patients.

Primary Outcome

Participants will listen to a list of 50 words and repeat each word aloud. Results are reported as a percentage of correctly repeated words out of 50.

Conditions Studied

Interventions

  • DEVICE DEEPSONIC™ Deep Sound Optimized Neural Integrated Chip Artificial intelligence-based noise reduction

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2025-04-24
Est. Completion 2027-01-01
Phase NA
Mayo Clinic

2,844 total trials

What NCT06743295 shows while recruiting

NCT06743295 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 6,112-participant average among 58 other Hearing Loss trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Hearing Loss appearing as the primary indexed condition, and to 1 intervention - of which DEEPSONIC™ Deep Sound Optimized Neural Integrated Chip Artificial intelligence-based noise reduction is the first listed.

NCT06743295 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06743295 about?

NCT06743295 is a clinical study titled "AI Noise Reduction in Phonak Hearing Aids". The purpose of this study is to determine if artificial intelligence- based noise reduction can offer objective improvement in hearing and speech perception for hearing impaired patients.

What is the current status of trial NCT06743295?

This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2025-04-24. Estimated completion is 2027-01-01.

What conditions does trial NCT06743295 study?

This clinical trial studies the following conditions: Hearing Loss.

What interventions are being tested in trial NCT06743295?

The interventions under investigation include: DEEPSONIC™ Deep Sound Optimized Neural Integrated Chip Artificial intelligence-based noise reduction (DEVICE).

Who is sponsoring clinical trial NCT06743295?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06743295 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hearing Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06743295's enrollment target sits among peer trials

500 16th of 58 higher than 43 of 58 other Hearing Loss trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06743295, the US trial registry maintained by the National Library of Medicine. NCT06743295 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.